The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with atorvastatin 20 mg in patients with low HDL
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
105
* JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment * Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments
* Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments * Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
Unnamed facility
Amsterdam, Amsterdam, Netherlands
% change from baseline in HDL-C; inhibition of CETP activity
Time frame: 4-weeks
% change from baseline in LDL-C and TC/HDL-C
Time frame: 4-weeks
Plasma concentration of JTT-705
Time frame: 4-weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.